These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 9219227)
1. Ribozymes. Their functions and strategies for their use. Gibson SA; Shillitoe EJ Mol Biotechnol; 1997 Apr; 7(2):125-37. PubMed ID: 9219227 [TBL] [Abstract][Full Text] [Related]
3. Biological and functional aspects of catalytic RNAs. Castanotto D; Rossi JJ; Deshler JO Crit Rev Eukaryot Gene Expr; 1992; 2(4):331-57. PubMed ID: 1486242 [TBL] [Abstract][Full Text] [Related]
4. Development of ribozymes for gene therapy. Sullivan SM J Invest Dermatol; 1994 Nov; 103(5 Suppl):85S-89S. PubMed ID: 7963690 [TBL] [Abstract][Full Text] [Related]
5. Anti-gene therapy: the use of ribozymes to inhibit gene function. Couture LA; Stinchcomb DT Trends Genet; 1996 Dec; 12(12):510-5. PubMed ID: 9257533 [TBL] [Abstract][Full Text] [Related]
6. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target. Phylactou LA; Tsipouras P; Kilpatrick MW Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217 [TBL] [Abstract][Full Text] [Related]
7. Ribozymes: recent advances in the development of RNA tools. Puerta-Fernández E; Romero-López C; Barroso-delJesus A; Berzal-Herranz A FEMS Microbiol Rev; 2003 Apr; 27(1):75-97. PubMed ID: 12697343 [TBL] [Abstract][Full Text] [Related]
8. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents. Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650 [TBL] [Abstract][Full Text] [Related]
13. A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target. Li YL; Torchet C; Vergne J; Maurel MC Biochimie; 2007 Oct; 89(10):1257-63. PubMed ID: 17703868 [TBL] [Abstract][Full Text] [Related]
14. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III. Denman RB; Smedman M; Kung L Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076 [TBL] [Abstract][Full Text] [Related]
16. The many faces of the hairpin ribozyme: structural and functional variants of a small catalytic RNA. Müller S; Appel B; Krellenberg T; Petkovic S IUBMB Life; 2012 Jan; 64(1):36-47. PubMed ID: 22131309 [TBL] [Abstract][Full Text] [Related]
17. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Mistry SJ; Benham CJ; Atweh GF Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):41-9. PubMed ID: 11258620 [TBL] [Abstract][Full Text] [Related]
18. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells. Hayashidani Y; Hiyama E; Murakami Y; Sueda T Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061 [TBL] [Abstract][Full Text] [Related]
19. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity. Sioud M J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719 [TBL] [Abstract][Full Text] [Related]